Sanofi Shares Bounce 2.55% Midday After Testing Key Support Level
Sanofi's stock has risen by 2.55% at midday on Wednesday, January 14, after testing its support threshold at 80.50 euros the previous day. This rebound occurs in a context marked by the European approval of Tzield to delay stage 3 type 1 diabetes, announced on January 12.
Market Performance and Technical Indicators
Sanofi's shares show a midday increase of 2.55% on Wednesday, January 14, reaching 82.55 euros compared to a closing price of 80.50 euros the day before. This rebound follows a challenging session on January 13, where the stock lost 2.32% and tested its technical support level at 80.50 euros. Trading volumes accounted for 0.14% of the capital, a moderate level but sufficient to materialize the recovery movement observed since the opening. Over the past week, the stock now shows a performance of 0.32%, while it remains down by 13.08% over the year, reflecting a still demanding sectoral context for large pharmaceutical companies. The RSI is at 42, in a neutral zone and slightly below the equilibrium of 50, indicating no overbought or oversold signals. The stock still trades below its 50-day moving average, positioned at 84.66 euros, about 2.5% above the current price. This gap illustrates the consolidation phase the stock has been going through for several weeks. The MACD displays a slightly positive histogram at 0.09, showing the beginning of a bullish divergence, yet without confirming a sustainable recovery trend. The technical resistance is located at 86.59 euros, a key level that the stock should surpass to regain a more pronounced bullish momentum.
Operational Context and Regulatory Announcements
The stock's rebound occurs in an operational context marked by several positive regulatory announcements. On January 12, the European Commission approved Tzield for delaying the onset of stage 3 type 1 diabetes in adult patients and children aged 8 years and older with stage 2 type 1 diabetes. This approval is an important step in strengthening the group's immunology portfolio. Sanofi also submitted on January 5 a request to extend the indication of Tzield to children from one year old, with an FDA priority review expected in April 2026. These advances are part of a therapeutic diversification strategy that has been underway for several quarters. Furthermore, at the end of December, the group finalized the acquisition of Dynavax Technologies for $2.2 billion, including the HEPLISAV B vaccine against hepatitis B for adults and a phase 1/2 vaccine candidate against shingles. Despite these strategic announcements, the market remains cautious about the stock's valuation. Analysts maintain predominantly positive recommendations: Grupo Santander retains an outperform recommendation with a target price of 106 euros, while Berenberg has a buy recommendation with a target of 105 euros, representing potential upsides of between 24 and 28% compared to the current price. The group will publish its fourth-quarter results on January 29.
